Laboratory Corporation of America® Holdings (LabCorp®) has announced the availability of Roche Diagnostics' Cytochrome AmpliChip™ P450 2D6/2C19 Genotyping and Phenotyping Assay as an enhancement to LabCorp's growing pharmacogenetics test menu.
Cleared by the U.S. Food and Drug Administration for diagnostic use, the assay utilizes DNA microarray technology to provide a method of identifying multiple genetic variants in two cytochrome P450 (CYP450) genes, CYP2D6 and CYP2C19.
These genes metabolize 40 to 45 percent of all prescription drugs, including antidepressants, pain relievers and cardiovascular agents.
Variants in these genes can cause individuals to metabolize certain medications slowly or quickly than normal, which can lead to serious side effects.
Identifying these variants can help healthcare providers select optimal drug doses for their patients and avoid potentially serious drug interactions.
"Because drugs do not work the same in all individuals, pharmacogenetic tests like those for CYP450 help physicians better understand gene-drug interactions and can make a significant difference in both quality and cost of patient care," said Myla Lai-Goldman, M.D., Executive Vice President, Chief Scientific Officer and Medical Director of LabCorp.
"Drugs and doses are typically adjusted, if needed, by trial and error, which may lead to a prolonged period before optimal therapy is achieved."
"Additionally, many drug reactions are due to inappropriate dosing, and unnecessarily high dosages cause unnecessary costs."